#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1.
1-1	0-2	1.	_	_	_	_

#Text=Introduction
2-1	3-15	Introduction	abstract	new	_	_

#Text=Primary liver cancer is the sixth most prevalent cancer and the second leading cause of cancer mortality worldwide .
3-1	16-23	Primary	abstract[3]	new[3]	coref	3-5[4_3]
3-2	24-29	liver	object|abstract[3]	new|new[3]	coref	4-5
3-3	30-36	cancer	abstract[3]	new[3]	_	_
3-4	37-39	is	_	_	_	_
3-5	40-43	the	abstract[4]|abstract[5]	giv[4]|giv[5]	coref|coref	3-5[5_4]|3-16[0_5]
3-6	44-49	sixth	abstract[4]|abstract[5]	giv[4]|giv[5]	_	_
3-7	50-54	most	abstract[4]|abstract[5]	giv[4]|giv[5]	_	_
3-8	55-64	prevalent	abstract[4]|abstract[5]	giv[4]|giv[5]	_	_
3-9	65-71	cancer	abstract[4]|abstract[5]	giv[4]|giv[5]	_	_
3-10	72-75	and	abstract[5]	giv[5]	_	_
3-11	76-79	the	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
3-12	80-86	second	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
3-13	87-94	leading	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
3-14	95-100	cause	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
3-15	101-103	of	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
3-16	104-110	cancer	abstract[5]|abstract[6]|abstract|event[8]	giv[5]|new[6]|giv|new[8]	coref	4-1[10_0]
3-17	111-120	mortality	abstract[5]|abstract[6]|event[8]	giv[5]|new[6]|new[8]	_	_
3-18	121-130	worldwide	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
3-19	131-132	.	_	_	_	_

#Text=The most common primary liver cancer is hepatocellular carcinoma ( HCC ) , which accounts for >85 % of all cases .
4-1	133-136	The	abstract[10]	giv[10]	coref	4-8[11_10]
4-2	137-141	most	abstract[10]	giv[10]	_	_
4-3	142-148	common	abstract[10]	giv[10]	_	_
4-4	149-156	primary	abstract[10]	giv[10]	_	_
4-5	157-162	liver	object|abstract[10]	giv|giv[10]	coref	6-11
4-6	163-169	cancer	abstract[10]	giv[10]	_	_
4-7	170-172	is	_	_	_	_
4-8	173-187	hepatocellular	abstract[11]	giv[11]	coref	21-8[0_11]
4-9	188-197	carcinoma	abstract[11]	giv[11]	_	_
4-10	198-199	(	_	_	_	_
4-11	200-203	HCC	abstract	new	coref	5-1
4-12	204-205	)	_	_	_	_
4-13	206-207	,	_	_	_	_
4-14	208-213	which	_	_	_	_
4-15	214-222	accounts	_	_	_	_
4-16	223-226	for	_	_	_	_
4-17	227-230	>85	abstract[13]	new[13]	coref	7-9[34_13]
4-18	231-232	%	abstract[13]	new[13]	_	_
4-19	233-235	of	abstract[13]	new[13]	_	_
4-20	236-239	all	abstract[13]|object[14]	new[13]|new[14]	_	_
4-21	240-245	cases	abstract[13]|object[14]	new[13]|new[14]	_	_
4-22	246-247	.	_	_	_	_

#Text=HCC predominantly arises in the setting of cirrhosis associated with hepatitis B and C virus infections , alcohol abuse , non-alcoholic steatohepatitis and metabolic diseases .
5-1	248-251	HCC	abstract	giv	coref	6-2
5-2	252-265	predominantly	_	_	_	_
5-3	266-272	arises	_	_	_	_
5-4	273-275	in	_	_	_	_
5-5	276-279	the	abstract[16]	new[16]	_	_
5-6	280-287	setting	abstract[16]	new[16]	_	_
5-7	288-290	of	abstract[16]	new[16]	_	_
5-8	291-300	cirrhosis	abstract[16]|substance[17]	new[16]|new[17]	_	_
5-9	301-311	associated	abstract[16]|substance[17]	new[16]|new[17]	_	_
5-10	312-316	with	abstract[16]|substance[17]	new[16]|new[17]	_	_
5-11	317-326	hepatitis	abstract[16]|substance[17]|abstract|abstract[22]	new[16]|new[17]|new|new[22]	_	_
5-12	327-328	B	abstract[16]|substance[17]|place|abstract[22]	new[16]|new[17]|new|new[22]	_	_
5-13	329-332	and	abstract[16]|substance[17]|abstract[22]	new[16]|new[17]|new[22]	_	_
5-14	333-334	C	abstract[16]|substance[17]|person|abstract[22]	new[16]|new[17]|new|new[22]	_	_
5-15	335-340	virus	abstract[16]|substance[17]|abstract|abstract[22]	new[16]|new[17]|new|new[22]	_	_
5-16	341-351	infections	abstract[16]|substance[17]|abstract[22]	new[16]|new[17]|new[22]	_	_
5-17	352-353	,	abstract[16]|substance[17]	new[16]|new[17]	_	_
5-18	354-361	alcohol	abstract[16]|substance[17]|event[23]	new[16]|new[17]|new[23]	_	_
5-19	362-367	abuse	abstract[16]|substance[17]|event[23]	new[16]|new[17]|new[23]	_	_
5-20	368-369	,	abstract[16]|substance[17]	new[16]|new[17]	_	_
5-21	370-383	non-alcoholic	abstract[16]|substance[17]|abstract[24]	new[16]|new[17]|new[24]	_	_
5-22	384-399	steatohepatitis	abstract[16]|substance[17]|abstract[24]	new[16]|new[17]|new[24]	_	_
5-23	400-403	and	abstract[16]|substance[17]	new[16]|new[17]	_	_
5-24	404-413	metabolic	abstract[16]|substance[17]|abstract[25]	new[16]|new[17]|new[25]	_	_
5-25	414-422	diseases	abstract[16]|substance[17]|abstract[25]	new[16]|new[17]|new[25]	_	_
5-26	423-424	.	_	_	_	_

#Text=Early-stage HCC patients are often subjected to surgical resection and liver transplantation .
6-1	425-436	Early-stage	person[27]	new[27]	coref	8-28[49_27]
6-2	437-440	HCC	abstract|person[27]	giv|new[27]	coref	9-12
6-3	441-449	patients	person[27]	new[27]	_	_
6-4	450-453	are	_	_	_	_
6-5	454-459	often	_	_	_	_
6-6	460-469	subjected	_	_	_	_
6-7	470-472	to	_	_	_	_
6-8	473-481	surgical	event[28]	new[28]	coref	7-7[0_28]
6-9	482-491	resection	event[28]	new[28]	_	_
6-10	492-495	and	_	_	_	_
6-11	496-501	liver	object|event[30]	giv|new[30]	coref|coref	7-15[0_30]|8-37
6-12	502-517	transplantation	event[30]	new[30]	_	_
6-13	518-519	.	_	_	_	_

#Text=However , 5-year recurrence rates after resection reach >70 % and the efficiency of transplantation is limited by organ shortage and technical issues .
7-1	520-527	However	_	_	_	_
7-2	528-529	,	_	_	_	_
7-3	530-536	5-year	abstract[32]	new[32]	coref	8-9[42_32]
7-4	537-547	recurrence	event|abstract[32]	new|new[32]	_	_
7-5	548-553	rates	abstract[32]	new[32]	_	_
7-6	554-559	after	abstract[32]	new[32]	_	_
7-7	560-569	resection	abstract[32]|event	new[32]|giv	_	_
7-8	570-575	reach	_	_	_	_
7-9	576-579	>70	abstract[34]	giv[34]	coref	8-13[44_34]
7-10	580-581	%	abstract[34]	giv[34]	_	_
7-11	582-585	and	_	_	_	_
7-12	586-589	the	abstract[35]	new[35]	_	_
7-13	590-600	efficiency	abstract[35]	new[35]	_	_
7-14	601-603	of	abstract[35]	new[35]	_	_
7-15	604-619	transplantation	abstract[35]|event	new[35]|giv	_	_
7-16	620-622	is	_	_	_	_
7-17	623-630	limited	_	_	_	_
7-18	631-633	by	_	_	_	_
7-19	634-639	organ	event[37]	new[37]	_	_
7-20	640-648	shortage	event[37]	new[37]	_	_
7-21	649-652	and	_	_	_	_
7-22	653-662	technical	abstract[38]	new[38]	_	_
7-23	663-669	issues	abstract[38]	new[38]	_	_
7-24	670-671	.	_	_	_	_

#Text=Although local ablation and transarterial chemoembolization respectively confer 5-year survival rates of 50 – 70 % and survival benefit of >6 months , they are confined to patients with single tumors or multinodular tumors with good liver reserve .
8-1	672-680	Although	_	_	_	_
8-2	681-686	local	abstract[39]	new[39]	_	_
8-3	687-695	ablation	abstract[39]	new[39]	_	_
8-4	696-699	and	_	_	_	_
8-5	700-713	transarterial	abstract[40]	new[40]	_	_
8-6	714-731	chemoembolization	abstract[40]	new[40]	_	_
8-7	732-744	respectively	_	_	_	_
8-8	745-751	confer	_	_	_	_
8-9	752-758	5-year	abstract[42]|abstract[43]	giv[42]|giv[43]	coref|ana	8-9[43_42]|8-24[0_43]
8-10	759-767	survival	event|abstract[42]|abstract[43]	new|giv[42]|giv[43]	coref	8-18
8-11	768-773	rates	abstract[42]|abstract[43]	giv[42]|giv[43]	_	_
8-12	774-776	of	abstract[42]|abstract[43]	giv[42]|giv[43]	_	_
8-13	777-779	50	abstract[42]|abstract[43]|abstract[44]	giv[42]|giv[43]|giv[44]	coref	13-19[96_44]
8-14	780-781	–	abstract[42]|abstract[43]|abstract[44]	giv[42]|giv[43]|giv[44]	_	_
8-15	782-784	70	abstract[42]|abstract[43]|abstract[44]	giv[42]|giv[43]|giv[44]	_	_
8-16	785-786	%	abstract[42]|abstract[43]|abstract[44]	giv[42]|giv[43]|giv[44]	_	_
8-17	787-790	and	abstract[43]	giv[43]	_	_
8-18	791-799	survival	abstract[43]|event|abstract[46]	giv[43]|giv|new[46]	coref	11-14[69_0]
8-19	800-807	benefit	abstract[43]|abstract[46]	giv[43]|new[46]	_	_
8-20	808-810	of	abstract[43]|abstract[46]	giv[43]|new[46]	_	_
8-21	811-813	>6	abstract[43]|abstract[46]|time[47]	giv[43]|new[46]|new[47]	coref	11-10[68_47]
8-22	814-820	months	abstract[43]|abstract[46]|time[47]	giv[43]|new[46]|new[47]	_	_
8-23	821-822	,	_	_	_	_
8-24	823-827	they	abstract	giv	_	_
8-25	828-831	are	_	_	_	_
8-26	832-840	confined	_	_	_	_
8-27	841-843	to	_	_	_	_
8-28	844-852	patients	person[49]	giv[49]	ana	11-3[0_49]
8-29	853-857	with	person[49]	giv[49]	_	_
8-30	858-864	single	person[49]|object[50]	giv[49]|new[50]	_	_
8-31	865-871	tumors	person[49]|object[50]	giv[49]|new[50]	_	_
8-32	872-874	or	person[49]	giv[49]	_	_
8-33	875-887	multinodular	person[49]|object[51]	giv[49]|new[51]	_	_
8-34	888-894	tumors	person[49]|object[51]	giv[49]|new[51]	_	_
8-35	895-899	with	person[49]	giv[49]	_	_
8-36	900-904	good	person[49]|abstract[53]	giv[49]|new[53]	_	_
8-37	905-910	liver	person[49]|object|abstract[53]	giv[49]|giv|new[53]	_	_
8-38	911-918	reserve	person[49]|abstract[53]	giv[49]|new[53]	_	_
8-39	919-920	.	_	_	_	_

#Text=Chemotherapy is not routinely used due to the chemoresistant character of HCC .
9-1	921-933	Chemotherapy	substance	new	_	_
9-2	934-936	is	_	_	_	_
9-3	937-940	not	_	_	_	_
9-4	941-950	routinely	_	_	_	_
9-5	951-955	used	_	_	_	_
9-6	956-959	due	_	_	_	_
9-7	960-962	to	_	_	_	_
9-8	963-966	the	abstract[55]	new[55]	_	_
9-9	967-981	chemoresistant	abstract[55]	new[55]	_	_
9-10	982-991	character	abstract[55]	new[55]	_	_
9-11	992-994	of	abstract[55]	new[55]	_	_
9-12	995-998	HCC	abstract[55]|abstract	new[55]|giv	coref	10-2[57_0]
9-13	999-1000	.	_	_	_	_

#Text=For advanced HCC , sorafenib , a multi-tyrosine kinase inhibitor ( MTKI ) , has been the only approved systemic first-line agent for over a decade , until lenvatinib , another MTKI , recently came into play .
10-1	1001-1004	For	_	_	_	_
10-2	1005-1013	advanced	abstract[57]	giv[57]	coref	12-34[0_57]
10-3	1014-1017	HCC	abstract[57]	giv[57]	_	_
10-4	1018-1019	,	_	_	_	_
10-5	1020-1029	sorafenib	substance	new	coref	10-17[62_0]
10-6	1030-1031	,	_	_	_	_
10-7	1032-1033	a	abstract[60]	new[60]	appos	10-12[0_60]
10-8	1034-1048	multi-tyrosine	abstract[60]	new[60]	_	_
10-9	1049-1055	kinase	abstract|abstract[60]	new|new[60]	_	_
10-10	1056-1065	inhibitor	abstract[60]	new[60]	_	_
10-11	1066-1067	(	_	_	_	_
10-12	1068-1072	MTKI	abstract	giv	appos	10-31[65_0]
10-13	1073-1074	)	_	_	_	_
10-14	1075-1076	,	_	_	_	_
10-15	1077-1080	has	_	_	_	_
10-16	1081-1085	been	_	_	_	_
10-17	1086-1089	the	substance[62]	giv[62]	_	_
10-18	1090-1094	only	substance[62]	giv[62]	_	_
10-19	1095-1103	approved	substance[62]	giv[62]	_	_
10-20	1104-1112	systemic	substance[62]	giv[62]	_	_
10-21	1113-1123	first-line	substance[62]	giv[62]	_	_
10-22	1124-1129	agent	substance[62]	giv[62]	_	_
10-23	1130-1133	for	substance[62]	giv[62]	_	_
10-24	1134-1138	over	substance[62]|time[63]	giv[62]|new[63]	_	_
10-25	1139-1140	a	substance[62]|time[63]	giv[62]|new[63]	_	_
10-26	1141-1147	decade	substance[62]|time[63]	giv[62]|new[63]	_	_
10-27	1148-1149	,	_	_	_	_
10-28	1150-1155	until	_	_	_	_
10-29	1156-1166	lenvatinib	substance	new	_	_
10-30	1167-1168	,	_	_	_	_
10-31	1169-1176	another	abstract[65]	giv[65]	_	_
10-32	1177-1181	MTKI	abstract[65]	giv[65]	_	_
10-33	1182-1183	,	_	_	_	_
10-34	1184-1192	recently	_	_	_	_
10-35	1193-1197	came	_	_	_	_
10-36	1198-1202	into	_	_	_	_
10-37	1203-1207	play	_	_	_	_
10-38	1208-1209	.	_	_	_	_

#Text=Yet , their clinical efficacy was suboptimal , with only ~3 months of prolonged survival .
11-1	1210-1213	Yet	_	_	_	_
11-2	1214-1215	,	_	_	_	_
11-3	1216-1221	their	person|abstract[67]	giv|new[67]	_	_
11-4	1222-1230	clinical	abstract[67]	new[67]	_	_
11-5	1231-1239	efficacy	abstract[67]	new[67]	_	_
11-6	1240-1243	was	_	_	_	_
11-7	1244-1254	suboptimal	_	_	_	_
11-8	1255-1256	,	_	_	_	_
11-9	1257-1261	with	_	_	_	_
11-10	1262-1266	only	time[68]	giv[68]	_	_
11-11	1267-1269	~3	time[68]	giv[68]	_	_
11-12	1270-1276	months	time[68]	giv[68]	_	_
11-13	1277-1279	of	time[68]	giv[68]	_	_
11-14	1280-1289	prolonged	time[68]|event[69]	giv[68]|giv[69]	coref	13-16[0_69]
11-15	1290-1298	survival	time[68]|event[69]	giv[68]|giv[69]	_	_
11-16	1299-1300	.	_	_	_	_

#Text=Second-line treatments include regorafenib and cabozantinib , also MTKIs ; nivolumab and pembrolizumab , immune checkpoint inhibitors targeting programmed death-1 ( PD-1 ) ; and ramucirumab , the first biomarker-driven therapeutics approved for HCC that targets the angiogenic vascular endothelial growth factor receptor ( VEGFR ) , all of which have not been established until the past few years and require further investigations .
12-1	1301-1312	Second-line	abstract[70]	new[70]	_	_
12-2	1313-1323	treatments	abstract[70]	new[70]	_	_
12-3	1324-1331	include	_	_	_	_
12-4	1332-1343	regorafenib	animal	new	_	_
12-5	1344-1347	and	_	_	_	_
12-6	1348-1360	cabozantinib	place	new	_	_
12-7	1361-1362	,	_	_	_	_
12-8	1363-1367	also	_	_	_	_
12-9	1368-1373	MTKIs	abstract	new	_	_
12-10	1374-1375	;	_	_	_	_
12-11	1376-1385	nivolumab	substance|abstract[75]	new|new[75]	appos	12-15[78_75]
12-12	1386-1389	and	abstract[75]	new[75]	_	_
12-13	1390-1403	pembrolizumab	abstract[75]|place	new[75]|new	_	_
12-14	1404-1405	,	_	_	_	_
12-15	1406-1412	immune	abstract[78]	giv[78]	_	_
12-16	1413-1423	checkpoint	place|abstract[78]	new|giv[78]	_	_
12-17	1424-1434	inhibitors	abstract[78]	giv[78]	_	_
12-18	1435-1444	targeting	abstract[78]	giv[78]	_	_
12-19	1445-1455	programmed	abstract[78]|event[79]	giv[78]|new[79]	_	_
12-20	1456-1463	death-1	abstract[78]|event[79]	giv[78]|new[79]	_	_
12-21	1464-1465	(	_	_	_	_
12-22	1466-1470	PD-1	abstract	new	_	_
12-23	1471-1472	)	_	_	_	_
12-24	1473-1474	;	_	_	_	_
12-25	1475-1478	and	_	_	_	_
12-26	1479-1490	ramucirumab	substance	new	_	_
12-27	1491-1492	,	_	_	_	_
12-28	1493-1496	the	abstract[82]	new[82]	coref	24-20[202_82]
12-29	1497-1502	first	abstract[82]	new[82]	_	_
12-30	1503-1519	biomarker-driven	abstract[82]	new[82]	_	_
12-31	1520-1532	therapeutics	abstract[82]	new[82]	_	_
12-32	1533-1541	approved	abstract[82]	new[82]	_	_
12-33	1542-1545	for	abstract[82]	new[82]	_	_
12-34	1546-1549	HCC	abstract[82]|abstract	new[82]|giv	coref	13-7
12-35	1550-1554	that	abstract[82]	new[82]	_	_
12-36	1555-1562	targets	abstract[82]	new[82]	_	_
12-37	1563-1566	the	abstract[82]|abstract[87]	new[82]|new[87]	appos	12-45[0_87]
12-38	1567-1577	angiogenic	abstract[82]|abstract[87]	new[82]|new[87]	_	_
12-39	1578-1586	vascular	abstract[82]|abstract[86]|abstract[87]	new[82]|new[86]|new[87]	coref	16-17[116_86]
12-40	1587-1598	endothelial	abstract[82]|abstract|abstract[86]|abstract[87]	new[82]|new|new[86]|new[87]	_	_
12-41	1599-1605	growth	abstract[82]|abstract|abstract[86]|abstract[87]	new[82]|new|new[86]|new[87]	coref	16-18
12-42	1606-1612	factor	abstract[82]|abstract[86]|abstract[87]	new[82]|new[86]|new[87]	_	_
12-43	1613-1621	receptor	abstract[82]|abstract[87]	new[82]|new[87]	_	_
12-44	1622-1623	(	abstract[82]	new[82]	_	_
12-45	1624-1629	VEGFR	abstract[82]|abstract	new[82]|giv	_	_
12-46	1630-1631	)	abstract[82]	new[82]	_	_
12-47	1632-1633	,	abstract[82]	new[82]	_	_
12-48	1634-1637	all	abstract[82]	new[82]	_	_
12-49	1638-1640	of	abstract[82]	new[82]	_	_
12-50	1641-1646	which	abstract[82]	new[82]	_	_
12-51	1647-1651	have	abstract[82]	new[82]	_	_
12-52	1652-1655	not	abstract[82]	new[82]	_	_
12-53	1656-1660	been	abstract[82]	new[82]	_	_
12-54	1661-1672	established	abstract[82]	new[82]	_	_
12-55	1673-1678	until	abstract[82]	new[82]	_	_
12-56	1679-1682	the	abstract[82]|time[89]	new[82]|new[89]	_	_
12-57	1683-1687	past	abstract[82]|time[89]	new[82]|new[89]	_	_
12-58	1688-1691	few	abstract[82]|time[89]	new[82]|new[89]	_	_
12-59	1692-1697	years	abstract[82]|time[89]	new[82]|new[89]	_	_
12-60	1698-1701	and	abstract[82]	new[82]	_	_
12-61	1702-1709	require	abstract[82]	new[82]	_	_
12-62	1710-1717	further	abstract[82]|abstract[90]	new[82]|new[90]	_	_
12-63	1718-1732	investigations	abstract[82]|abstract[90]	new[82]|new[90]	_	_
12-64	1733-1734	.	_	_	_	_

#Text=So far , treatment outcomes for HCC are far from satisfactory , with a 5-year survival rate of only ~18 % .
13-1	1735-1737	So	_	_	_	_
13-2	1738-1741	far	_	_	_	_
13-3	1742-1743	,	_	_	_	_
13-4	1744-1753	treatment	event|abstract[92]	new|new[92]	coref	23-12[193_0]
13-5	1754-1762	outcomes	abstract[92]	new[92]	_	_
13-6	1763-1766	for	abstract[92]	new[92]	_	_
13-7	1767-1770	HCC	abstract[92]|abstract	new[92]|giv	coref	14-15
13-8	1771-1774	are	_	_	_	_
13-9	1775-1778	far	_	_	_	_
13-10	1779-1783	from	_	_	_	_
13-11	1784-1796	satisfactory	_	_	_	_
13-12	1797-1798	,	_	_	_	_
13-13	1799-1803	with	_	_	_	_
13-14	1804-1805	a	abstract[95]	new[95]	_	_
13-15	1806-1812	5-year	abstract[95]	new[95]	_	_
13-16	1813-1821	survival	event|abstract[95]	giv|new[95]	_	_
13-17	1822-1826	rate	abstract[95]	new[95]	_	_
13-18	1827-1829	of	abstract[95]	new[95]	_	_
13-19	1830-1834	only	abstract[95]|abstract[96]	new[95]|giv[96]	_	_
13-20	1835-1838	~18	abstract[95]|abstract[96]	new[95]|giv[96]	_	_
13-21	1839-1840	%	abstract[95]|abstract[96]	new[95]|giv[96]	_	_
13-22	1841-1842	.	_	_	_	_

#Text=Evidently , there is an urgent need to develop more effective therapeutic strategies in HCC .
14-1	1843-1852	Evidently	_	_	_	_
14-2	1853-1854	,	_	_	_	_
14-3	1855-1860	there	_	_	_	_
14-4	1861-1863	is	_	_	_	_
14-5	1864-1866	an	abstract[97]	new[97]	_	_
14-6	1867-1873	urgent	abstract[97]	new[97]	_	_
14-7	1874-1878	need	abstract[97]	new[97]	_	_
14-8	1879-1881	to	abstract[97]	new[97]	_	_
14-9	1882-1889	develop	abstract[97]	new[97]	_	_
14-10	1890-1894	more	abstract[97]|abstract[98]	new[97]|new[98]	_	_
14-11	1895-1904	effective	abstract[97]|abstract[98]	new[97]|new[98]	_	_
14-12	1905-1916	therapeutic	abstract[97]|abstract[98]	new[97]|new[98]	_	_
14-13	1917-1927	strategies	abstract[97]|abstract[98]	new[97]|new[98]	_	_
14-14	1928-1930	in	abstract[97]	new[97]	_	_
14-15	1931-1934	HCC	abstract[97]|abstract	new[97]|giv	coref	15-20
14-16	1935-1936	.	_	_	_	_

#Text=Signal transducer and activator of transcription 3 ( STAT3 ) has recently emerged as a potential therapeutic target for HCC due to its crucial roles in oncogenesis .
15-1	1937-1943	Signal	abstract[100]	new[100]	_	_
15-2	1944-1954	transducer	abstract[100]	new[100]	_	_
15-3	1955-1958	and	_	_	_	_
15-4	1959-1968	activator	abstract[101]	new[101]	appos	15-9[0_101]
15-5	1969-1971	of	abstract[101]	new[101]	_	_
15-6	1972-1985	transcription	abstract[101]|abstract[102]	new[101]|new[102]	coref	17-9[0_102]
15-7	1986-1987	3	abstract[101]|abstract[102]	new[101]|new[102]	_	_
15-8	1988-1989	(	_	_	_	_
15-9	1990-1995	STAT3	abstract	giv	coref	16-1
15-10	1996-1997	)	_	_	_	_
15-11	1998-2001	has	_	_	_	_
15-12	2002-2010	recently	_	_	_	_
15-13	2011-2018	emerged	_	_	_	_
15-14	2019-2021	as	_	_	_	_
15-15	2022-2023	a	abstract[104]	new[104]	_	_
15-16	2024-2033	potential	abstract[104]	new[104]	_	_
15-17	2034-2045	therapeutic	abstract[104]	new[104]	_	_
15-18	2046-2052	target	abstract[104]	new[104]	_	_
15-19	2053-2056	for	abstract[104]	new[104]	_	_
15-20	2057-2060	HCC	abstract[104]|abstract	new[104]|giv	ana	15-23
15-21	2061-2064	due	_	_	_	_
15-22	2065-2067	to	_	_	_	_
15-23	2068-2071	its	abstract|abstract[107]	giv|new[107]	coref|coref	20-13[173_107]|23-12
15-24	2072-2079	crucial	abstract[107]	new[107]	_	_
15-25	2080-2085	roles	abstract[107]	new[107]	_	_
15-26	2086-2088	in	abstract[107]	new[107]	_	_
15-27	2089-2100	oncogenesis	abstract[107]|abstract	new[107]|new	_	_
15-28	2101-2102	.	_	_	_	_

#Text=STAT3 was initially determined to control acute-phase genes in response to interleukin-6 ( IL-6 ) and epidermal growth factor ( EGF ) during inflammation .
16-1	2103-2108	STAT3	abstract	giv	coref	20-7
16-2	2109-2112	was	_	_	_	_
16-3	2113-2122	initially	_	_	_	_
16-4	2123-2133	determined	_	_	_	_
16-5	2134-2136	to	_	_	_	_
16-6	2137-2144	control	_	_	_	_
16-7	2145-2156	acute-phase	abstract[110]	new[110]	_	_
16-8	2157-2162	genes	abstract[110]	new[110]	_	_
16-9	2163-2165	in	_	_	_	_
16-10	2166-2174	response	abstract[111]	new[111]	_	_
16-11	2175-2177	to	abstract[111]	new[111]	_	_
16-12	2178-2191	interleukin-6	abstract[111]|abstract	new[111]|new	appos	16-14
16-13	2192-2193	(	_	_	_	_
16-14	2194-2198	IL-6	abstract	giv	_	_
16-15	2199-2200	)	_	_	_	_
16-16	2201-2204	and	_	_	_	_
16-17	2205-2214	epidermal	animal|abstract[116]	new|giv[116]	appos	16-21[0_116]
16-18	2215-2221	growth	abstract|abstract[116]	giv|giv[116]	coref	20-21
16-19	2222-2228	factor	abstract[116]	giv[116]	_	_
16-20	2229-2230	(	_	_	_	_
16-21	2231-2234	EGF	abstract	giv	ana	17-1
16-22	2235-2236	)	_	_	_	_
16-23	2237-2243	during	_	_	_	_
16-24	2244-2256	inflammation	event	new	_	_
16-25	2257-2258	.	_	_	_	_

#Text=It belongs to the STAT family of cytoplasmic transcription factors that mediate signal transduction from the plasma membrane to the nucleus in various cellular activities .
17-1	2259-2261	It	abstract	giv	coref	22-9[188_0]
17-2	2262-2269	belongs	_	_	_	_
17-3	2270-2272	to	_	_	_	_
17-4	2273-2276	the	abstract[121]	new[121]	coref	18-1[130_121]
17-5	2277-2281	STAT	person|abstract[121]	new|new[121]	_	_
17-6	2282-2288	family	abstract[121]	new[121]	_	_
17-7	2289-2291	of	abstract[121]	new[121]	_	_
17-8	2292-2303	cytoplasmic	abstract[121]|abstract[123]	new[121]|new[123]	_	_
17-9	2304-2317	transcription	abstract[121]|abstract|abstract[123]	new[121]|giv|new[123]	_	_
17-10	2318-2325	factors	abstract[121]|abstract[123]	new[121]|new[123]	_	_
17-11	2326-2330	that	abstract[121]|abstract[123]	new[121]|new[123]	_	_
17-12	2331-2338	mediate	abstract[121]|abstract[123]	new[121]|new[123]	_	_
17-13	2339-2345	signal	abstract[121]|abstract[123]|abstract|abstract[125]	new[121]|new[123]|new|new[125]	_	_
17-14	2346-2358	transduction	abstract[121]|abstract[123]|abstract[125]	new[121]|new[123]|new[125]	_	_
17-15	2359-2363	from	abstract[121]|abstract[123]	new[121]|new[123]	_	_
17-16	2364-2367	the	abstract[121]|abstract[123]|place[127]	new[121]|new[123]|new[127]	_	_
17-17	2368-2374	plasma	abstract[121]|abstract[123]|abstract|place[127]	new[121]|new[123]|new|new[127]	_	_
17-18	2375-2383	membrane	abstract[121]|abstract[123]|place[127]	new[121]|new[123]|new[127]	_	_
17-19	2384-2386	to	abstract[121]|abstract[123]	new[121]|new[123]	_	_
17-20	2387-2390	the	abstract[121]|abstract[123]|place[128]	new[121]|new[123]|new[128]	_	_
17-21	2391-2398	nucleus	abstract[121]|abstract[123]|place[128]	new[121]|new[123]|new[128]	_	_
17-22	2399-2401	in	abstract[121]|abstract[123]	new[121]|new[123]	_	_
17-23	2402-2409	various	abstract[121]|abstract[123]|event[129]	new[121]|new[123]|new[129]	_	_
17-24	2410-2418	cellular	abstract[121]|abstract[123]|event[129]	new[121]|new[123]|new[129]	_	_
17-25	2419-2429	activities	abstract[121]|abstract[123]|event[129]	new[121]|new[123]|new[129]	_	_
17-26	2430-2431	.	_	_	_	_

#Text=The STAT family comprises seven members : STAT1 , 2 , 3 , 4 , 5a , 5b and 6 .
18-1	2432-2435	The	abstract[130]	giv[130]	_	_
18-2	2436-2440	STAT	abstract[130]	giv[130]	_	_
18-3	2441-2447	family	abstract[130]	giv[130]	_	_
18-4	2448-2457	comprises	_	_	_	_
18-5	2458-2463	seven	abstract[131]	new[131]	appos	18-8[132_131]
18-6	2464-2471	members	abstract[131]	new[131]	_	_
18-7	2472-2473	:	_	_	_	_
18-8	2474-2479	STAT1	abstract[132]	giv[132]	appos	18-10[0_132]
18-9	2480-2481	,	abstract[132]	giv[132]	_	_
18-10	2482-2483	2	abstract[132]|abstract	giv[132]|giv	appos	18-16
18-11	2484-2485	,	_	_	_	_
18-12	2486-2487	3	abstract	new	_	_
18-13	2488-2489	,	_	_	_	_
18-14	2490-2491	4	abstract	new	_	_
18-15	2492-2493	,	_	_	_	_
18-16	2494-2496	5a	abstract	giv	appos	18-18
18-17	2497-2498	,	_	_	_	_
18-18	2499-2501	5b	abstract	giv	ana	19-3
18-19	2502-2505	and	_	_	_	_
18-20	2506-2507	6	abstract	new	ana	19-1[139_0]
18-21	2508-2509	.	_	_	_	_

#Text=Each of them consists of ( i ) an N-terminal domain for oligomerization , ( ii ) a coiled-coil domain for interaction with regulatory proteins , ( iii ) a DNA-binding domain for recognition of specific DNA sequences , ( iv ) a Src homology-2 ( SH2 ) domain that triggers phosphorylation and dimerization after docking to phosphorylated receptors and ( iv ) a C-terminal transactivation domain with specific tyrosine ( Y ) ( present in all STATs ) and serine ( S ) residues ( absent in STAT2 and 6 ) that are phosphorylated upon transcriptional activation .
19-1	2510-2514	Each	abstract[139]	giv[139]	coref	19-91[0_139]
19-2	2515-2517	of	abstract[139]	giv[139]	_	_
19-3	2518-2522	them	abstract[139]|abstract	giv[139]|giv	_	_
19-4	2523-2531	consists	_	_	_	_
19-5	2532-2534	of	_	_	_	_
19-6	2535-2536	(	_	_	_	_
19-7	2537-2538	i	_	_	_	_
19-8	2539-2540	)	_	_	_	_
19-9	2541-2543	an	abstract[141]	new[141]	_	_
19-10	2544-2554	N-terminal	abstract[141]	new[141]	_	_
19-11	2555-2561	domain	abstract[141]	new[141]	_	_
19-12	2562-2565	for	abstract[141]	new[141]	_	_
19-13	2566-2581	oligomerization	abstract[141]|abstract	new[141]|new	_	_
19-14	2582-2583	,	_	_	_	_
19-15	2584-2585	(	_	_	_	_
19-16	2586-2588	ii	_	_	_	_
19-17	2589-2590	)	_	_	_	_
19-18	2591-2592	a	object[143]	new[143]	_	_
19-19	2593-2604	coiled-coil	object[143]	new[143]	_	_
19-20	2605-2611	domain	object[143]	new[143]	_	_
19-21	2612-2615	for	object[143]	new[143]	_	_
19-22	2616-2627	interaction	object[143]|abstract[144]	new[143]|new[144]	_	_
19-23	2628-2632	with	object[143]|abstract[144]	new[143]|new[144]	_	_
19-24	2633-2643	regulatory	object[143]|abstract[144]|substance[145]	new[143]|new[144]|new[145]	_	_
19-25	2644-2652	proteins	object[143]|abstract[144]|substance[145]	new[143]|new[144]|new[145]	_	_
19-26	2653-2654	,	_	_	_	_
19-27	2655-2656	(	_	_	_	_
19-28	2657-2660	iii	_	_	_	_
19-29	2661-2662	)	_	_	_	_
19-30	2663-2664	a	abstract[147]	new[147]	_	_
19-31	2665-2676	DNA-binding	abstract|abstract[147]	new|new[147]	_	_
19-32	2677-2683	domain	abstract[147]	new[147]	_	_
19-33	2684-2687	for	abstract[147]	new[147]	_	_
19-34	2688-2699	recognition	abstract[147]|abstract[148]	new[147]|new[148]	_	_
19-35	2700-2702	of	abstract[147]|abstract[148]	new[147]|new[148]	_	_
19-36	2703-2711	specific	abstract[147]|abstract[148]|abstract[150]	new[147]|new[148]|new[150]	_	_
19-37	2712-2715	DNA	abstract[147]|abstract[148]|abstract|abstract[150]	new[147]|new[148]|new|new[150]	_	_
19-38	2716-2725	sequences	abstract[147]|abstract[148]|abstract[150]	new[147]|new[148]|new[150]	_	_
19-39	2726-2727	,	_	_	_	_
19-40	2728-2729	(	_	_	_	_
19-41	2730-2732	iv	_	_	_	_
19-42	2733-2734	)	_	_	_	_
19-43	2735-2736	a	abstract[154]	new[154]	_	_
19-44	2737-2740	Src	abstract|abstract[152]|abstract[154]	new|new[152]|new[154]	appos	19-47[0_152]
19-45	2741-2751	homology-2	abstract[152]|abstract[154]	new[152]|new[154]	_	_
19-46	2752-2753	(	abstract[154]	new[154]	_	_
19-47	2754-2757	SH2	abstract|abstract[154]	giv|new[154]	_	_
19-48	2758-2759	)	abstract[154]	new[154]	_	_
19-49	2760-2766	domain	abstract[154]	new[154]	_	_
19-50	2767-2771	that	abstract[154]	new[154]	_	_
19-51	2772-2780	triggers	abstract[154]	new[154]	_	_
19-52	2781-2796	phosphorylation	abstract[154]|abstract	new[154]|new	_	_
19-53	2797-2800	and	abstract[154]	new[154]	_	_
19-54	2801-2813	dimerization	abstract[154]|event	new[154]|new	_	_
19-55	2814-2819	after	_	_	_	_
19-56	2820-2827	docking	_	_	_	_
19-57	2828-2830	to	_	_	_	_
19-58	2831-2845	phosphorylated	object[157]	new[157]	_	_
19-59	2846-2855	receptors	object[157]	new[157]	_	_
19-60	2856-2859	and	_	_	_	_
19-61	2860-2861	(	_	_	_	_
19-62	2862-2864	iv	_	_	_	_
19-63	2865-2866	)	_	_	_	_
19-64	2867-2868	a	abstract[159]	new[159]	_	_
19-65	2869-2879	C-terminal	abstract[159]	new[159]	_	_
19-66	2880-2895	transactivation	abstract|abstract[159]	new|new[159]	_	_
19-67	2896-2902	domain	abstract[159]	new[159]	_	_
19-68	2903-2907	with	abstract[159]	new[159]	_	_
19-69	2908-2916	specific	abstract[159]|abstract[160]	new[159]|new[160]	appos	19-72[0_160]
19-70	2917-2925	tyrosine	abstract[159]|abstract[160]	new[159]|new[160]	_	_
19-71	2926-2927	(	_	_	_	_
19-72	2928-2929	Y	abstract	giv	_	_
19-73	2930-2931	)	_	_	_	_
19-74	2932-2933	(	_	_	_	_
19-75	2934-2941	present	_	_	_	_
19-76	2942-2944	in	_	_	_	_
19-77	2945-2948	all	abstract[162]	new[162]	_	_
19-78	2949-2954	STATs	abstract[162]	new[162]	_	_
19-79	2955-2956	)	_	_	_	_
19-80	2957-2960	and	_	_	_	_
19-81	2961-2967	serine	animal|abstract[164]	new|new[164]	_	_
19-82	2968-2969	(	abstract[164]	new[164]	_	_
19-83	2970-2971	S	abstract[164]	new[164]	_	_
19-84	2972-2973	)	abstract[164]	new[164]	_	_
19-85	2974-2982	residues	abstract[164]	new[164]	_	_
19-86	2983-2984	(	abstract[164]	new[164]	_	_
19-87	2985-2991	absent	abstract[164]	new[164]	_	_
19-88	2992-2994	in	abstract[164]	new[164]	_	_
19-89	2995-3000	STAT2	abstract[164]|abstract	new[164]|new	_	_
19-90	3001-3004	and	abstract[164]	new[164]	_	_
19-91	3005-3006	6	abstract[164]|abstract	new[164]|giv	_	_
19-92	3007-3008	)	abstract[164]	new[164]	_	_
19-93	3009-3013	that	abstract[164]	new[164]	_	_
19-94	3014-3017	are	abstract[164]	new[164]	_	_
19-95	3018-3032	phosphorylated	abstract[164]	new[164]	_	_
19-96	3033-3037	upon	abstract[164]	new[164]	_	_
19-97	3038-3053	transcriptional	abstract[164]|event[167]	new[164]|new[167]	_	_
19-98	3054-3064	activation	abstract[164]|event[167]	new[164]|new[167]	_	_
19-99	3065-3066	.	_	_	_	_

#Text=Intensive investigation has been done on STAT3 since its discovery , revealing its physiological roles in early embryonic development , growth and differentiation of various adult tissues .
20-1	3067-3076	Intensive	abstract[168]	new[168]	_	_
20-2	3077-3090	investigation	abstract[168]	new[168]	_	_
20-3	3091-3094	has	_	_	_	_
20-4	3095-3099	been	_	_	_	_
20-5	3100-3104	done	_	_	_	_
20-6	3105-3107	on	_	_	_	_
20-7	3108-3113	STAT3	abstract	giv	ana	20-9
20-8	3114-3119	since	_	_	_	_
20-9	3120-3123	its	abstract|event[171]	giv|new[171]	ana	20-13
20-10	3124-3133	discovery	event[171]	new[171]	_	_
20-11	3134-3135	,	_	_	_	_
20-12	3136-3145	revealing	_	_	_	_
20-13	3146-3149	its	abstract|abstract[173]	giv|giv[173]	ana|coref	21-4|21-4[179_173]
20-14	3150-3163	physiological	abstract[173]	giv[173]	_	_
20-15	3164-3169	roles	abstract[173]	giv[173]	_	_
20-16	3170-3172	in	abstract[173]	giv[173]	_	_
20-17	3173-3178	early	abstract[173]|event[174]	giv[173]|new[174]	coref	24-15[200_174]
20-18	3179-3188	embryonic	abstract[173]|event[174]	giv[173]|new[174]	_	_
20-19	3189-3200	development	abstract[173]|event[174]	giv[173]|new[174]	_	_
20-20	3201-3202	,	abstract[173]	giv[173]	_	_
20-21	3203-3209	growth	abstract[173]|abstract	giv[173]|giv	_	_
20-22	3210-3213	and	abstract[173]	giv[173]	_	_
20-23	3214-3229	differentiation	abstract[173]|event[176]	giv[173]|new[176]	_	_
20-24	3230-3232	of	abstract[173]|event[176]	giv[173]|new[176]	_	_
20-25	3233-3240	various	abstract[173]|event[176]|object[177]	giv[173]|new[176]|new[177]	_	_
20-26	3241-3246	adult	abstract[173]|event[176]|object[177]	giv[173]|new[176]|new[177]	_	_
20-27	3247-3254	tissues	abstract[173]|event[176]|object[177]	giv[173]|new[176]|new[177]	_	_
20-28	3255-3256	.	_	_	_	_

#Text=In addition , its pathogenic roles in cancer initiation , progression , metastasis , chemoresistance and immunoevasion have been uncovered .
21-1	3257-3259	In	_	_	_	_
21-2	3260-3268	addition	_	_	_	_
21-3	3269-3270	,	_	_	_	_
21-4	3271-3274	its	abstract|abstract[179]	giv|giv[179]	coref|coref	22-4|24-7[196_179]
21-5	3275-3285	pathogenic	abstract[179]	giv[179]	_	_
21-6	3286-3291	roles	abstract[179]	giv[179]	_	_
21-7	3292-3294	in	abstract[179]	giv[179]	_	_
21-8	3295-3301	cancer	abstract[179]|abstract|event[181]	giv[179]|giv|new[181]	_	_
21-9	3302-3312	initiation	abstract[179]|event[181]	giv[179]|new[181]	_	_
21-10	3313-3314	,	abstract[179]	giv[179]	_	_
21-11	3315-3326	progression	abstract[179]|event	giv[179]|new	_	_
21-12	3327-3328	,	abstract[179]	giv[179]	_	_
21-13	3329-3339	metastasis	abstract[179]|abstract	giv[179]|new	_	_
21-14	3340-3341	,	abstract[179]	giv[179]	_	_
21-15	3342-3357	chemoresistance	abstract[179]|abstract	giv[179]|new	_	_
21-16	3358-3361	and	abstract[179]	giv[179]	_	_
21-17	3362-3375	immunoevasion	abstract[179]|abstract	giv[179]|new	_	_
21-18	3376-3380	have	_	_	_	_
21-19	3381-3385	been	_	_	_	_
21-20	3386-3395	uncovered	_	_	_	_
21-21	3396-3397	.	_	_	_	_

#Text=To date , STAT3 is widely recognized as an oncogenic factor in diverse human cancers .
22-1	3398-3400	To	_	_	_	_
22-2	3401-3405	date	time	new	_	_
22-3	3406-3407	,	_	_	_	_
22-4	3408-3413	STAT3	abstract	giv	coref	23-4
22-5	3414-3416	is	_	_	_	_
22-6	3417-3423	widely	_	_	_	_
22-7	3424-3434	recognized	_	_	_	_
22-8	3435-3437	as	_	_	_	_
22-9	3438-3440	an	abstract[188]	giv[188]	_	_
22-10	3441-3450	oncogenic	abstract[188]	giv[188]	_	_
22-11	3451-3457	factor	abstract[188]	giv[188]	_	_
22-12	3458-3460	in	abstract[188]	giv[188]	_	_
22-13	3461-3468	diverse	abstract[188]|abstract[189]	giv[188]|new[189]	_	_
22-14	3469-3474	human	abstract[188]|abstract[189]	giv[188]|new[189]	_	_
22-15	3475-3482	cancers	abstract[188]|abstract[189]	giv[188]|new[189]	_	_
22-16	3483-3484	.	_	_	_	_

#Text=Therefore , targeting STAT3 might be an attractive therapeutic strategy for HCC treatment .
23-1	3485-3494	Therefore	_	_	_	_
23-2	3495-3496	,	_	_	_	_
23-3	3497-3506	targeting	_	_	_	_
23-4	3507-3512	STAT3	abstract	giv	coref	24-11
23-5	3513-3518	might	_	_	_	_
23-6	3519-3521	be	_	_	_	_
23-7	3522-3524	an	abstract[191]	new[191]	_	_
23-8	3525-3535	attractive	abstract[191]	new[191]	_	_
23-9	3536-3547	therapeutic	abstract[191]	new[191]	_	_
23-10	3548-3556	strategy	abstract[191]	new[191]	_	_
23-11	3557-3560	for	abstract[191]	new[191]	_	_
23-12	3561-3564	HCC	abstract[191]|abstract|event[193]	new[191]|giv|giv[193]	coref	24-13
23-13	3565-3574	treatment	abstract[191]|event[193]	new[191]|giv[193]	_	_
23-14	3575-3576	.	_	_	_	_

#Text=In this review , we summarize the oncogenic roles of STAT3 in HCC and the current clinical development of STAT3-targeted therapeutics .
24-1	3577-3579	In	_	_	_	_
24-2	3580-3584	this	abstract[194]	new[194]	_	_
24-3	3585-3591	review	abstract[194]	new[194]	_	_
24-4	3592-3593	,	_	_	_	_
24-5	3594-3596	we	person	acc	_	_
24-6	3597-3606	summarize	_	_	_	_
24-7	3607-3610	the	abstract[196]|abstract[197]	giv[196]|giv[197]	coref	24-7[197_196]
24-8	3611-3620	oncogenic	abstract[196]|abstract[197]	giv[196]|giv[197]	_	_
24-9	3621-3626	roles	abstract[196]|abstract[197]	giv[196]|giv[197]	_	_
24-10	3627-3629	of	abstract[196]|abstract[197]	giv[196]|giv[197]	_	_
24-11	3630-3635	STAT3	abstract[196]|abstract[197]|abstract	giv[196]|giv[197]|giv	_	_
24-12	3636-3638	in	abstract[196]|abstract[197]	giv[196]|giv[197]	_	_
24-13	3639-3642	HCC	abstract[196]|abstract[197]|abstract	giv[196]|giv[197]|giv	_	_
24-14	3643-3646	and	abstract[197]	giv[197]	_	_
24-15	3647-3650	the	abstract[197]|event[200]	giv[197]|giv[200]	_	_
24-16	3651-3658	current	abstract[197]|event[200]	giv[197]|giv[200]	_	_
24-17	3659-3667	clinical	abstract[197]|event[200]	giv[197]|giv[200]	_	_
24-18	3668-3679	development	abstract[197]|event[200]	giv[197]|giv[200]	_	_
24-19	3680-3682	of	abstract[197]|event[200]	giv[197]|giv[200]	_	_
24-20	3683-3697	STAT3-targeted	abstract[197]|event[200]|abstract|abstract[202]	giv[197]|giv[200]|new|giv[202]	_	_
24-21	3698-3710	therapeutics	abstract[197]|event[200]|abstract[202]	giv[197]|giv[200]|giv[202]	_	_
24-22	3711-3712	.	_	_	_	_
